All News

Novartis' Zelnorm is back, but only through a restricted-access program.

A new study says obesity is like a social virus, so why is the obesity-drug market just sitting there?

August 2008 CE

The US healthcare system may be broken, as such sages as Michael Moore suggest, but it's not likely to be fixed as long as our domestic debate remains stuck on the cost of prescription drugs. Meanwhile, obesity and diabetes are becoming national epidemics. Talk about sicko.

Severin Schwan takes over at Roche

Tainted batches of Viracept pulled from European shelves.

Spending expected to increase mildly in the short term

In the wake of a high-profile death from counterfeit drugs, the industry reacts

But is the pharma-biotech vaccine deal a prelude to a takeover?

It was a short, sweaty week complete with fireworks....

...And the spurned suitor won't take "No" for an answer

All hell broke loose on May 21 when the New England Journal of Medicine released Cleveland Clinic cardiologist Dr. Steven Nissen's meta-analysis of 42 studies of Avandia, showing a 43 percent increased risk of heart attack.

The Acomplia story isn't ending. It's just beginning. Get ready to see what happens when a much-desired drug is marketed by people accountable to no one.

If pharma is seen as a genuine contributor to the policy debate on comparative effectiveness, it could influence funding, pricing, and coverage decisions

Or: No news is good news--for everyone but us reporters

Blockbuster antidepressants linked to bone loss in seniors

Catching up with the first ouchless fast test on National HIV Testing Day

July 2007 CE

Big crop of oncology drugs is the fruit of Garnier's excellent restructuring

New lawsuit against activists shows CEO Miles White maverick MO

Maraviroc's promise shows the value of expanded-access programs

FDA fears may prevent a showdown between two weight-loss heavyweights.

The take-home from the American Society of Clinical Oncology.

But no news is good news for a drug?s safety profile, a new study says

Biotech takes issue with move to limit reimbursement.

Active Care Network and biotech partners aim to increase patient compliance.

Drug makers find it hard to recoup development costs, report finds.

Restasis goes against the grain of Rx-to-OTC switching.

June 2007 CE

It's not FDA's job to make doctors and patients take more responsibility for using drugs wisely. But whose job is it? Really, whose?